Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

Abstract Background Novel human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugates prompt the identification of the HER2-low subtype. However, the biological significance of HER2-low expression in breast cancer is unclear. Methods Clinical and genomic data of 579 metastatic...

Full description

Bibliographic Details
Main Authors: Juan Jin, Bin Li, Jianing Cao, Ting Li, Jian Zhang, Jun Cao, Mingchuan Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xichun Hu
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Journal of Translational Medicine
Subjects:
HER2-low breast cancer
Antibody–drug conjugates
HER2 expression
HER2 dynamics
Metastatic breast cancer
Heterogeneity
Online Access:https://doi.org/10.1186/s12967-023-04076-9

Internet

https://doi.org/10.1186/s12967-023-04076-9

Similar Items